المؤلفون: Bolgar, A. N., Zotova, J. I., Kirichenko, D. D., Besedin, I. S., Semenov, A. V., Shaikhaidarov, R. S., Astafiev, O. V.

المصدر: Phys. Rev. Lett. 120, 223603, (2017)

مصطلحات موضوعية: Quantum Physics

الوصول الحر: http://arxiv.org/abs/1710.06476Test

المؤلفون: Surianinov M. H., Neutov S. F., Soroka M. M., Kirichenko D. O., Chuchmai O. M.

المصدر: World Science; No 6(78) (2022): World Science ; World Science; № 6(78) (2022): World Science ; 2414-6404 ; 2413-1032

مصطلحات موضوعية: Concrete, Hingeless Arch, Hydrostatic Pressure, Bearing Capacity, Numerical Analysis, Experiment

وصف الملف: application/pdf

العلاقة: https://rsglobal.pl/index.php/ws/article/view/2437/2110Test; https://rsglobal.pl/index.php/ws/article/view/2437Test

الإتاحة: https://doi.org/10.31435/rsglobal_ws/30122022/7904Test
https://rsglobal.pl/index.php/ws/article/view/2437Test

المؤلفون: Kirichenko, E O, Kirichenko, D P, Zaitsev, D V

المصدر: Journal of Physics: Conference Series ; volume 2211, issue 1, page 012012 ; ISSN 1742-6588 1742-6596

الإتاحة: https://doi.org/10.1088/1742-6596/2211/1/012012Test

المؤلفون: N. Kniajeskaia P., E. Anaev H., A. Belevskiy S., A. Kameleva A., E. Safoshkina V., N. Kirichenko D., Н. Княжеская П., Э. Анаев Х., А. Белевский С., А. Камелева А., Е. Сафошкина В., Н. Кириченко Д.

المصدر: Meditsinskiy sovet = Medical Council; № 16 (2021); 17-25 ; Медицинский Совет; № 16 (2021); 17-25 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: phenotype, endotype, atopy, IgE, monoclonal antibodies, target therapy, anti-IgE-therapy, basal membrane, smooth bronchial muscles, sputum eosinophilia, FeNO, bronchial asthma, фенотипы, эндотипы, моноклональные антитела, анти-IgE-терапия, базальная мембрана, гладкая мускулатура бронхов, эозинофилия мокроты, бронхиальная астма

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/6455/5845Test; Чучалин А.Г. Бронхиальная астма. М.: Медицина; 1985. 160 с. Режим доступа: https://studfile.net/preview/1564756Test/.; Dahlén S.E. Asthma phenotyping: noninvasive biomarkers suitable for bedside science are the next step to implement precision medicine. J Intern Med. 2016;279(2):205–207. https://doi.org/10.1111/joim.12466Test.; Ishizaka T., Ishizaka K., Johansson S.G., Bennich H. Histamine release from human leukocytes by anti-gamma E antibodies. J Immunol. 1969;102(4): 884–892. Available at: https://www.jimmunol.org/content/102/4/884/tabarticle-infoTest.; Ishizaka K., Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol. 1967;99(6):1187–1198. Available at: https://www.jimmunol.org/content/99/6/1187.longTest.; Johansson S.G. Discovery and development of IgE assays. Clin Exp Allergy. 1997;27(1 Suppl.):60–63. https://doi.org/10.1111/j.1365-2222.1997.tb01828.xTest.; Johansson S.G., Hourihane J.O., Bousquet J., Bruijnzeel-Koomen C., Dreborg S., Haahtela T. et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56(9):813–824. https://doi.org/10.1034/j.1398-9995.2001.t01-1-00001.xTest.; Johansson S.G. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet. 1967;2(7523):951–953. https://doi.org/10.1016/s0140-6736Test(67)90792-1.; Stanworth D.R. The discovery of IgE. Allergy. 1993;48(2):67–71. https://doi.org/10.1111/j.1398-9995.1993.tb00687.xTest.; Johansson S.G. The History of IgE: From discovery to 2010. Curr Allergy Asthma Rep. 2011;11(2):173–177. https://doi.org/10.1007/s11882-010-0174-3Test.; Мачарадзе Д.Ш. Современные клинические аспекты оценки уровней общего и специфических IgE. Педиатрия. Журнал имени Г.Н. Сперанского. 2017;96(2):121–127. Режим доступа: https://pediatriajournal.ru/archive?show=357&section=4881Test.; Lloyd C.M., Robinson D.S. Allergen-induced airway remodelling. Eur Respir J. 2007;29(5):1020–1032. https://doi.org/10.1183/09031936.00150305Test.; Romagnoli M., Caramori G., Braccioni F., Ravenna F., Barreiro E., Siafakas N.M. et al. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy. 2007;37(4):552–557. https://doi.org/10.1111/j.1365-2222.2007.02683.xTest.; Osborne M., Deffebach M. The epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. Ann Allergy Asthma Immunol. 2004;92(1):3. https://doi.org/10.1016/S1081-1206Test(10)61702-4.; Pearce N., Beasley R., Crane J., Burgess C., Jackson R. End of the New Zealand asthma mortality epidemic. Lancet. 1995;345(8941):41–44. https://doi.org/10.1016/s0140-6736Test(95)91159-6.; Kinoshita H., Kubota A., Kasuda S., Nishiguchi M., Ouchi H., Minami T. et al. An autopsy case of asthmatic death – usefulness of biochemical examination. Vojnosanit Pregl. 2008;65(5):404–406. https://doi.org/10.2298/vsp0805404kTest.; Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111): 1225–1232. https://doi.org/10.1016/S0140-6736Test(97)07302-9.; Asher M.I., Stewart A.W., Mallol J., Montefort S., Lai C.K., Aït-Khaled N., Odhiambo J. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. Respir Res. 2010;11(1):8. https://doi.org/10.1186/1465-9921-11-8Test.; Shaaban R., Zureik M., Soussan D., Neukirch C., Heinrich J., Sunyer J. et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049–1057. https://doi.org/10.1016/S0140-6736Test(08)61446-4.; Fokkens W., Lund V., Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007;20:1–136. Available at: https://pubmed.ncbi.nlm.nih.gov/17844873Test/.; Brożek J.L., Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. https://doi.org/10.1016/j.jaci.2017.03.050Test.; Kwah J.H., Peters A.T. Nasal polyps and rhinosinusitis. Allergy Asthma Proc. 2019;40(6):380–384. https://doi.org/10.2500/aap.2019.40.4252Test.; Agache I., Beltran J., Akdis C., Akdis M., Canelo-Aybar C., Canonica G.W. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. https://doi.org/10.1111/all.14221Test.; Molimard M., Mala L., Bourdeix I., Le Gros V. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med. 2014;108(4):571–576. https://doi.org/10.1016/j.rmed.2014.02.003Test.; Козлов В.А., Савченко А.А., Кудрявцев И.В., Козлов И.Г., Кудлай Д.А., Продеус А.П., Борисов А.Г. Клиническая иммунология. Красноярск: Поликор; 2020. 386 с. https://doi.org/10.17513/np.438Test.; Gandhi N.A., Pirozzi G., Graham N.M.H. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. https://doi.org/10.1080/1744666X.2017.1298443Test.; Castro M., Zangrilli J., Wechsler M.E., Bateman E.D., Brusselle G.G., Bardin P. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. https://doi.org/10.1016/S2213-2600Test(15)00042-9.; Ortega H.G., Yancey S.W., Mayer B., Gunsoy N.B., Keene O.N., Bleecker E.R. et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. https://doi.org/10.1016/S2213-2600Test(16)30031-5.; Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. https://doi.org/10.1016/S0140-6736Test(16)31324-1.; Иванов Р., Секарёва Г., Кравцова О., Кудлай Д., Лукьянов С., Тихонова И. и др. Правила проведения исследований биоаналоговых лекарственных средств (биоаналогов). Фармакокинетика и фармакодинамика. 2014;(1):21–36. Режим доступа: https://www.pharmacokinetica.ru/jour/article/view/138Test.; Ненашева Н.М., Аверьянов А.В., Ильина Н.И., Авдеев С.Н., Осипова Г.Л., Рубаник Т.В. и др. Сравнительное изучение клинической эффективности биоаналогичного препарата Генолар® по результатам рандомизированного клинического исследования III фазы. Пульмонология. 2020;30(6): 782–796. https://doi.org/10.18093/0869-0189-2020-30-6-782-796Test.; Palomares Ó., Sánchez-Ramón S., Dávila I., Prieto L., Pérez de Llano L., Lleonart M. et al. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. Int J Mol Sci. 2017;18(6):1328. https://doi.org/10.3390/ijms18061328Test.; Ayres J.G., Higgins B., Chilvers E.R., Ayre G., Blogg M., Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59(7):701–708. https://doi.org/10.1111/j.1398-9995.2004.00533.xTest.; Heymann P.W., Platts-Mills T.A.E., Woodfolk J.A., Borish L., Murphy D.D., Carper H.T. et al. Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE. J Allergy Clin Immunol. 2020;146(3):545–554. https://doi.org/10.1016/j.jaci.2020.01.035Test.; Henriksen D.P., Bodtger U., Sidenius K., Maltbaek N., Pedersen L., Madsen H. et al. Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol. 2020;16:49. https://doi.org/10.1186/s13223-020-00442-0Test.; Pfaller B., José Yepes-Nuñez J., Agache I., Akdis C.A., Alsalamah M., Bavbek S. et al. Biologicals in atopic disease in pregnancy: An EAACI position paper. Allergy. 2021;76(1):71–89. https://doi.org/10.1111/all.14282Test.; Djukanović R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F. et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593. https://doi.org/10.1164/rccm.200312-1651OCTest.; Van Rensen E.L., Evertse C.E., van Schadewijk W.A., van Wijngaarden S., Ayre G., Mauad T. et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64(1):72–80. https://doi.org/10.1111/j.1398-9995.2008.01881.xTest.; Noga O., Hanf G., Brachmann I., Klucken A.C., Kleine-Tebbe J., Rosseau S. et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117(6):1493–1499. https://doi.org/10.1016/j.jaci.2006.02.028Test.; Simeone-Penney M.C., Severgnini M., Rozo L., Takahashi S., Cochran B.H., Simon A.R. PDGF-induced human airway smooth muscle cell proliferation requires STAT3 and the small GTPase Rac1. Am J Physiol Lung Cell Mol Physiol. 2008;294(4):L698–L704. https://doi.org/10.1152/ajplung.00529.2007Test.; Rabe K.F., Calhoun W.J., Smith N., Jimenez P. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy. 2011;66(9):1142–1145. https://doi.org/10.1111/j.1398-9995.2011.02617.xTest.; Dal Negro R.W., Micheletto C., De Ferrari L., Folli C., Chiappori A., Canonica G.W. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25(2):475–484. https://doi.org/10.1177/039463201202500217Test.; Riccio A.M., Mauri P., De Ferrari L., Rossi R., Di Silvestre D., Benazzi L. et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin Transl Allergy. 2017;7:6. https://doi.org/10.1186/s13601-017-0143-1Test.; Solidoro P., Patrucco F., de Blasio F., Brussino L., Bellocchia M., Dassetto D. et al. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. Ther Adv Respir Dis. 2019;13:1753466619841274. https://doi.org/10.1177/1753466619841274Test.; Hoshino M., Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83(6):520–528. https://doi.org/10.1159/000334701Test.; Tajiri T., Niimi A., Matsumoto H., Ito I., Oguma T., Otsuka K. et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a timeseries observational study. Ann Allergy Asthma Immunol. 2014;113(4):470.e2–475.e2. https://doi.org/10.1016/j.anai.2014.06.004Test.; Pan S., Conaway S. Jr, Deshpande D.A. Mitochondrial regulation of airway smooth muscle functions in health and pulmonary diseases. Arch Biochem Biophys. 2019;663:109–119. https://doi.org/10.1016/j.abb.2019.01.002Test.; Roth M., Zhao F., Zhong J., Lardinois D., Tamm M. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS ONE. 2015;10(9):e0136549. https://doi.org/10.1371/journal.pone.0136549Test.; Roth M., Tamm M. The effects of omalizumab on IgE induced cytokine synthesis by asthmatic airway smooth muscle cells. Ann Allergy Asthma Immunol. 2010;104(2):152–160. https://doi.org/10.1016/j.anai.2009.11.022Test.; Vennera M.D.C., Sabadell C., Picado C. Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma. Thorax. 2018;73(8):782–784. https://doi.org/10.1136/thoraxjnl-2017-210017Test.; Baena-Cagnani C.E., Teijeiro A., Canonica G.W. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr Opin Allergy Clin Immunol. 2015;15(3):267–271. https://doi.org/10.1097/ACI.0000000000000161Test.; Kim D.H., Park K.Y., Kim B.J., Kim M.N., Mun S.K. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38(5):496–500. https://doi.org/10.1111/j.1365-2230.2012.04438.xTest.; Naclerio R.M., Baroody F.M., Pinto J.M. Should clinicians use omalizumab for the treatment of nasal polyps? J Allergy Clin Immunol. 2013;132(1):247. https://doi.org/10.1016/j.jaci.2013.04.001Test.; Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W. et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110.e1–116.e1. https://doi.org/10.1016/j.jaci.2012.07.047Test.; https://www.med-sovet.pro/jour/article/view/6455Test

الإتاحة: https://doi.org/10.21518/2079-701X-2021-16-17-25Test
https://doi.org/10.1111/joim.12466Test
https://doi.org/10.1111/j.1365-2222.1997.tb01828.xTest
https://doi.org/10.1034/j.1398-9995.2001.t01-1-00001.xTest
https://doi.org/10.1016/s0140-6736Test(67)90792-1
https://doi.org/10.1111/j.1398-9995.1993.tb00687.xTest
https://doi.org/10.1007/s11882-010-0174-3Test
https://doi.org/10.1183/09031936.00150305Test
https://doi.org/10.1111/j.1365-2222.2007.02683.xTest
https://doi.org/10.1016/S1081-1206Test(10)61702-4

المؤلفون: Surianinov, M, Neutov, S, Korneieva, I, Kirichenko, D

المصدر: IOP Conference Series: Materials Science and Engineering ; volume 1162, issue 1, page 012017 ; ISSN 1757-8981 1757-899X

الإتاحة: https://doi.org/10.1088/1757-899x/1162/1/012017Test

المؤلفون: Surianinov, M, Kirichenko, D, Korneieva, I, Neutov, S

المصدر: IOP Conference Series: Materials Science and Engineering ; volume 1162, issue 1, page 012016 ; ISSN 1757-8981 1757-899X

الإتاحة: https://doi.org/10.1088/1757-899x/1162/1/012016Test

المؤلفون: Surianinov, M, Neutov, S, Korneieva, I, Kirichenko, D

المصدر: IOP Conference Series: Materials Science and Engineering ; volume 1164, issue 1, page 012035 ; ISSN 1757-8981 1757-899X

الإتاحة: https://doi.org/10.1088/1757-899x/1164/1/012035Test

المؤلفون: Kirichenko, D V, Balakirev, S V, Chernenko, N E, Eremenko, M M, Solodovnik, M S

المصدر: Journal of Physics: Conference Series ; volume 2086, issue 1, page 012017 ; ISSN 1742-6588 1742-6596

الإتاحة: https://doi.org/10.1088/1742-6596/2086/1/012017Test

المؤلفون: Kunts, K A, Kirichenko, D P, Bykovskaya, E F, Zaitsev, D V, Kabov, O A

المصدر: Journal of Physics: Conference Series ; volume 1677, issue 1, page 012139 ; ISSN 1742-6588 1742-6596

الإتاحة: https://doi.org/10.1088/1742-6596/1677/1/012139Test

المؤلفون: Broman, K.K., Hughes, T.M., Bredbeck, B.C., Sun, J., Kirichenko, D., Carr, M.J., Sharma, A., Bartlett, E.K., Nijhuis, A.A.G., Thompson, J.F., Hieken, T.J., Kottschade, L., Downs, J., Gyorki, D.E., Stahlie, E., van Akkooi, A., Ollila, D.W., O'shea, K., Song, Y., Karakousis, G.

المصدر: http://dx.doi.org/10.1097/sla.0000000000005370Test.

مصطلحات موضوعية: International High Risk Melanoma Consortium

العلاقة: http://purl.org/au-research/grants/nhmrc/APP1093017Test; Annals of Surgery, 2023; 277(5):e1106-e1115; https://hdl.handle.net/2440/138853Test; Kroon, H.M. [0000-0002-8923-7527]

الإتاحة: https://doi.org/10.1097/sla.0000000000005370Test
https://hdl.handle.net/2440/138853Test